EF-M2
1 paper5 findings
- 1 lab in 1 country
- Funder: Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- Animals1
Outcomes
5Inflammation
downin dogs1
1 study
Inflammation
downin dogs1
EF-M2 decreases inflammation in dogs.
“Prespecified pharmacodynamic markers shifted in directions consistent with M2-skewing (ARG1:iNOS ratio and IL-10 increased; TNF-α decreased) by day 7.”
Animalssubcutaneous0.1 μg/kg7 daysn = 60
Veterinary sciences9 Dec 2025
Transepidermal water loss
downin dogs1
1 study
Transepidermal water loss
downin dogs1
EF-M2 decreases transepidermal water loss in dogs (-1.35 g/m2·h).
“reduced transepidermal water loss (-1.35 g/m2·h, -2.45 to -0.25; p = 0.02)”
Animalssubcutaneous0.1 μg/kg4 weeksn = 60
Veterinary sciences9 Dec 2025
BAER auditory threshold
upin dogs1
1 study
BAER auditory threshold
upin dogs1
EF-M2 improves BAER auditory threshold in dogs (-5.28 dB).
“lower BAER auditory threshold (-5.28 dB, -7.53 to -3.04; p < 0.001)”
Animalssubcutaneous0.1 μg/kg4 weeksn = 60
Veterinary sciences9 Dec 2025
Vitality composite
upin dogs1
1 study
Vitality composite
upin dogs1
EF-M2 improves vitality composite in dogs (+2.01 z-units).
“+2.01 z-units at day 28 (95% CI, 1.52-2.50; p < 0.001)”
Animalssubcutaneous0.1 μg/kg4 weeksn = 60
Veterinary sciences9 Dec 2025
Active minutes/day
upin dogs1
1 study
Active minutes/day
upin dogs1
EF-M2 improves active minutes/day in dogs (+23.05 min/day).
“EF-M2 was superior to placebo on both: +23.05 min/day at week 1 (95% CI, 18.16-27.94; p < 0.001)”
Animalssubcutaneous0.1 μg/kg1 weekn = 60
Veterinary sciences9 Dec 2025